Real-World data dive: Palbociclib's impact on breast cancer care
NCT ID NCT06495164
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study looks at how the drug Palbociclib is actually used in everyday medical practice for people with a specific type of advanced breast cancer (HR+/HER2-). Researchers will analyze anonymous medical records to see how long patients take the drug and how it affects their need for chemotherapy later. The goal is to understand real-world treatment patterns and outcomes, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.